THERAMetrics holding AG (SIX: TMX) reports solid progress in the global partnering process for a series of key projects

Stans, Switzerland, February 17, 2014 - THERAMetrics has made significant progress since the global partnering process was initiated a few months ago for a series of key molecules with secured intellectual property and Orphan Drug Designation. These projects include pediatric and adult respiratory indications, infectious diseases and hyperproliferative disorders. Currently more than 40 companies across global markets are reviewing confidential information and some interested parties have already entered the negotiation phase. In this dynamic process THERAMetrics continues to recruit potential partners in Europe, the Middle East, USA and ASIA and is confident to finalize development and licensing agreements with partners within 3-6 months. The business model accepted by companies entering the evaluation phase involves funding phase III development in exchange for commercial rights in their respective territories post-approval. THERAMetrics has also approached a series of patient advocacy groups, private foundations, and governmental funding agencies and expects considerable project sponsorship to occur. About THERAMetricsTHERAMetrics holding AG is a tech-based Contract Research & Development Organisation dedicated to provide a full range of technological solutions through the entire value chain of drug discovery and development. The company, listed at the SIX Swiss Exchange (TMX) and located in Stans (Switzerland). For further information please contact: THERAMetrics holding AG Investor and External Relations Tel.: +41 79 285 37 81 [email protected] Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning THERAMetrics holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of THERAMetrics holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. THERAMetrics holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.